MRNS Quote, Financials, Valuation and Earnings

Amgen has a net margin of -283.63% compared to Marinus Pharmaceuticals's net margin of 33.28%. Marinus Pharmaceuticals's return on equity of -1150.43% beat Amgen's return on equity of 65.35%.

Marinus Pharmaceuticals has a consensus price target of $8.78, signalling upside risk potential of 470.25%. On the other hand Amgen has an analysts' consensus of $322.43 which suggests that it could grow by 21.91%. Given that Marinus Pharmaceuticals has higher upside potential than Amgen, analysts believe Marinus Pharmaceuticals is more attractive than Amgen.

Marinus Pharmaceuticals has a beta of 1.253, which suggesting that the stock is 25.343% more volatile than S&P 500. In comparison Amgen has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.307%.

Marinus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.4% to investors and pays a quarterly dividend of $2.25 per share. Marinus Pharmaceuticals pays -- of its earnings as a dividend. Amgen pays out 67.83% of its earnings as a dividend. Amgen's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Marinus Pharmaceuticals quarterly revenues are $8.5M, which are smaller than Amgen quarterly revenues of $8.5B. Marinus Pharmaceuticals's net income of -$24.2M is lower than Amgen's net income of $2.8B. Notably, Marinus Pharmaceuticals's price-to-earnings ratio is -- while Amgen's PE ratio is 33.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marinus Pharmaceuticals is 0.47x versus 4.38x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -283.63% compared to Marinus Pharmaceuticals's net margin of -49.65%. Marinus Pharmaceuticals's return on equity of -1150.43% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Marinus Pharmaceuticals has a consensus price target of $8.78, signalling upside risk potential of 470.25%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Marinus Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Marinus Pharmaceuticals.

Marinus Pharmaceuticals has a beta of 1.253, which suggesting that the stock is 25.343% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Marinus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marinus Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Marinus Pharmaceuticals quarterly revenues are $8.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Marinus Pharmaceuticals's net income of -$24.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Marinus Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marinus Pharmaceuticals is 0.47x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -283.63% compared to Marinus Pharmaceuticals's net margin of -2357.27%. Marinus Pharmaceuticals's return on equity of -1150.43% beat Palatin Technologies's return on equity of --.

Marinus Pharmaceuticals has a consensus price target of $8.78, signalling upside risk potential of 470.25%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1617.17%. Given that Palatin Technologies has higher upside potential than Marinus Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Marinus Pharmaceuticals.

Marinus Pharmaceuticals has a beta of 1.253, which suggesting that the stock is 25.343% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Marinus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marinus Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Marinus Pharmaceuticals quarterly revenues are $8.5M, which are larger than Palatin Technologies quarterly revenues of $350K. Marinus Pharmaceuticals's net income of -$24.2M is lower than Palatin Technologies's net income of -$7.8M. Notably, Marinus Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marinus Pharmaceuticals is 0.47x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -283.63% compared to Marinus Pharmaceuticals's net margin of --. Marinus Pharmaceuticals's return on equity of -1150.43% beat Viking Therapeutics's return on equity of --.

Marinus Pharmaceuticals has a consensus price target of $8.78, signalling upside risk potential of 470.25%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 159.74%. Given that Marinus Pharmaceuticals has higher upside potential than Viking Therapeutics, analysts believe Marinus Pharmaceuticals is more attractive than Viking Therapeutics.

Marinus Pharmaceuticals has a beta of 1.253, which suggesting that the stock is 25.343% more volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.884, suggesting its less volatile than the S&P 500 by 11.566%.

Marinus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marinus Pharmaceuticals pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Marinus Pharmaceuticals quarterly revenues are $8.5M, which are larger than Viking Therapeutics quarterly revenues of --. Marinus Pharmaceuticals's net income of -$24.2M is higher than Viking Therapeutics's net income of -$24.9M. Notably, Marinus Pharmaceuticals's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marinus Pharmaceuticals is 0.47x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.